NCT02550548View on ClinicalTrials.gov

Incretin Action in Physiology and Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

April 21, 2016

Primary Completion Date

April 16, 2021

Study Completion Date

April 16, 2021

Conditions
Insulin Secretion
Interventions
DRUG

GIP infusion

after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused

DRUG

GLP-1 infusion

after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused

DRUG

Ex-9 infusion

Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)

Trial Locations (1)

27705

Duke Center for Living, Durham

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

David D'Alessio, M.D.

OTHER

NCT02550548 - Incretin Action in Physiology and Diabetes | Biotech Hunter | Biotech Hunter